Biomm

Biomm P/B

The P/B (Price-to-Book Ratio) of Biomm (BIOM3.SA) as of Nov 16, 2026 is 2.68. In the previous year, P/B (Price-to-Book Ratio) was 3.19 — a change of -16.18% (lower).

P/B

2.68

YoY

-16.18%

Last updated:

P/B (Price-to-Book Ratio) of Biomm is 2025 2.68 . P/B (Price-to-Book Ratio) of Biomm was 2024 3.19 . It decreases by -16.18% lower compared to the previous year.

The Biomm P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
7.91 BRL
Jan 1, 2019
5.46 BRL
Jan 1, 2020
4.38 BRL
Jan 1, 2021
7.52 BRL
Jan 1, 2022
5.27 BRL
Jan 1, 2023
6.82 BRL
Jan 1, 2024
3.19 BRL
Jan 1, 2025
2.68 BRL
The Biomm P/B history
YEARP/BYoY
2.68-16.18%
3.19-53.22%
6.82+29.42%
5.27-29.87%
7.52+71.60%
4.38-19.80%
5.46-30.91%
7.91-44.10%
14.15+11.18%
12.72+74.62%
7.29-6.97%
7.83—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomm Stock analysis

What does Biomm do? Biomm SA generates revenue through the development and licensing of technology for producing human insulin and other recombinant proteins. The company's patented technology, protected in multiple regions, is used by pharmaceutical firms to manufacture therapeutic proteins for drugs and biopharmaceuticals. Its subsidiaries Biomm International Inc, Biomm Middle East Inc, and Biomm Russia Ltd support global operations. The firm also develops production processes for enzymes used in biomass hydrolysis and bio-fuel manufacturing, targeting industrial applications in renewable energy sectors. The primary buyers of Biomm SA's technology are pharmaceutical companies seeking to produce therapeutic proteins. These firms license the company's patented insulin production methods to integrate into their drug manufacturing processes. The enzyme production technology is sold to companies in the bio-fuel industry, particularly those involved in biomass conversion for renewable energy. Biomm SA's focus on recombinant protein production and bio-fuel applications positions it within the biotechnology and renewable energy markets. The company's business model relies on technology licensing fees and sales of proprietary production processes. Insulin production technology, protected by international patents, forms a significant revenue stream. Enzyme technology for biomass hydrolysis and bio-fuel manufacturing provides additional income from industrial clients. Biomm SA's subsidiaries facilitate international market access, enabling the company to serve global clients across pharmaceutical and renewable energy sectors. Biomm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomm stock

P/B (Price-to-Book Ratio) of Biomm is 2.68 in 2025.

P/B (Price-to-Book Ratio) of Biomm changed from 3.19 to 2.68, representing a -16.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Biomm since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Biomm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomm

All Key Metrics — Biomm